eribulin (Halaven)

Description

Eribulin is a synthetic analog of halichondrin B, classified as a microtubule dynamics inhibitor chemotherapy agent. It is primarily FDA-approved for metastatic breast cancer and liposarcoma, but has been explored in colorectal cancer through clinical trials. In CRC, eribulin is typically considered for patients with advanced disease who have progressed on standard therapies, particularly in the context of HER2-positive tumors or as part of combination regimens.

Mechanism of Action

Eribulin works by binding to the plus ends of microtubules and inhibiting microtubule polymerization without affecting depolymerization, leading to irreversible mitotic blockade. This unique mechanism differs from other microtubule-targeting agents, as it sequesters tubulin into nonproductive aggregates and triggers apoptosis through prolonged mitotic arrest.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials